Simple, safe and transparent(?): Preliminary reflections on the proposal for a new EU regulation of clinical trials

Research output: Contribution to journalArticle

Abstract

A significant reform is currently under the scrutiny of EU institutions in the field of pharmaceutical risk regulation. With its proposal dated July 17th 2012, the Commission seeks to modernise the legal framework of clinical trials by addressing a series of shortcomings ascribed to the current regime governed by Directive 2001/20/EC (to be repealed by the new legislation). The iter of the reform is proving to be complex and lengthy, the first vote having been delayed to March 2014.While a comprehensive account of such a detailed proposal would defeat the scope of this short report, the analysis will focus on some of the most salient features of the proposed regulation, and attempt to situate them in the international context of pharmaceutical regulation.
Original languageEnglish
Pages (from-to)534-538
Number of pages5
JournalEuropean Journal of Risk Regulation
Volume4
Issue number4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Drug products
EU
regulation
pharmaceutical
first vote
reform
European Community
legislation
regime

Cite this

@article{3c2449d3cf2144cfa25f553dc19d1422,
title = "Simple, safe and transparent(?): Preliminary reflections on the proposal for a new EU regulation of clinical trials",
abstract = "A significant reform is currently under the scrutiny of EU institutions in the field of pharmaceutical risk regulation. With its proposal dated July 17th 2012, the Commission seeks to modernise the legal framework of clinical trials by addressing a series of shortcomings ascribed to the current regime governed by Directive 2001/20/EC (to be repealed by the new legislation). The iter of the reform is proving to be complex and lengthy, the first vote having been delayed to March 2014.While a comprehensive account of such a detailed proposal would defeat the scope of this short report, the analysis will focus on some of the most salient features of the proposed regulation, and attempt to situate them in the international context of pharmaceutical regulation.",
author = "Marco Rizzi",
year = "2013",
doi = "10.1017/S1867299X00003172",
language = "English",
volume = "4",
pages = "534--538",
journal = "European Journal of Risk Regulation",
issn = "1867-299X",
publisher = "Lexxion",
number = "4",

}

TY - JOUR

T1 - Simple, safe and transparent(?): Preliminary reflections on the proposal for a new EU regulation of clinical trials

AU - Rizzi, Marco

PY - 2013

Y1 - 2013

N2 - A significant reform is currently under the scrutiny of EU institutions in the field of pharmaceutical risk regulation. With its proposal dated July 17th 2012, the Commission seeks to modernise the legal framework of clinical trials by addressing a series of shortcomings ascribed to the current regime governed by Directive 2001/20/EC (to be repealed by the new legislation). The iter of the reform is proving to be complex and lengthy, the first vote having been delayed to March 2014.While a comprehensive account of such a detailed proposal would defeat the scope of this short report, the analysis will focus on some of the most salient features of the proposed regulation, and attempt to situate them in the international context of pharmaceutical regulation.

AB - A significant reform is currently under the scrutiny of EU institutions in the field of pharmaceutical risk regulation. With its proposal dated July 17th 2012, the Commission seeks to modernise the legal framework of clinical trials by addressing a series of shortcomings ascribed to the current regime governed by Directive 2001/20/EC (to be repealed by the new legislation). The iter of the reform is proving to be complex and lengthy, the first vote having been delayed to March 2014.While a comprehensive account of such a detailed proposal would defeat the scope of this short report, the analysis will focus on some of the most salient features of the proposed regulation, and attempt to situate them in the international context of pharmaceutical regulation.

U2 - 10.1017/S1867299X00003172

DO - 10.1017/S1867299X00003172

M3 - Article

VL - 4

SP - 534

EP - 538

JO - European Journal of Risk Regulation

JF - European Journal of Risk Regulation

SN - 1867-299X

IS - 4

ER -